As part of the Cancer Drugs Fund (CDF) transitional arrangements, NICE committed to conducting a Single Technology Appraisal of acute lymphoblastic leukaemia (previously treated) - clofarabine [ID1033]. As such, a formal referral of this topic was received in June 2016. NICE have discussed the current suitability of this topic for the technology appraisal work programme with NHS England, now that further information has become available during the early scoping process of the appraisal. Clofarabine has a significant off label use in clinical practice, especially in the paediatric and young adult setting (whilst clofarabine is licensed as a single agent its standard use is in combination with other agents). In view of this, as well as the fact that the patent for the technology is shortly due to expire, NICE and NHS England regards that a commissioning decision would be best taken by the CDF ‘off label process’ feeding into the NHS England Specialised Commissioning Policy Development prioritisation process. As a consequence, the NICE STA will be discontinued. CDF transition funding will remain in place until a commissioning decision is taken by the CDF ‘off label process’.
 
Status Discontinued
Process STA pre-2018
ID number 1033

Project Team

Project lead Liv Gualda

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence

Timeline

Key events during the development of the guidance:

Date Update
01 December 2016 Discontinued, As part of the Cancer Drugs Fund (CDF) transitional arrangements, NICE committed to conducting a Single Technology Appraisal of acute lymphoblastic leukaemia (previously treated) - clofarabine [ID1033]. As such, a formal referral of this topic was received in June 2016. NICE have discussed the current suitability of this topic for the technology appraisal work programme with NHS England, now that further information has become available during the early scoping process of the appraisal. Clofarabine has a significant off label use in clinical practice, especially in the paediatric and young adult setting (whilst clofarabine is licensed as a single agent its standard use is in combination with other agents). In view of this, as well as the fact that the patent for the technology is shortly due to expire, NICE and NHS England regards that a commissioning decision would be best taken by the CDF ‘off label process’ feeding into the NHS England Specialised Commissioning Policy Development prioritisation process. As a consequence, the NICE STA will be discontinued. CDF transition funding will remain in place until a commissioning decision is taken by the CDF ‘off label process’.
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance